Yuyu Pharma Valuation

Q: What is the Fair Price of A000227 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A000227 (₩10530) is trading below our estimate of [[fair value]] (₩164783.76)

Is A000227 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A000227 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A000227 (₩10530) is trading below our estimate of fair value (₩164783.76)

Significantly Below Fair Value: A000227 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A000227?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for A000227. This is calculated by dividing A000227's market cap by their current preferred multiple.
What is A000227's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	₩73.79b

A000227 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.6x
Enterprise Value/EBITDA	6.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A000227's PE Ratio compare to its peers?

The above table shows the PE ratio for A000227 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	15.4x
A044960 Eagle Veterinary TechnologyLtd	21.4x	n/a	₩63.5b
A067290 JW Shinyak	29.9x	n/a	₩84.5b
A012790 Sinil Pharmaceutical	5.2x	n/a	₩82.5b
A001540 Ahn-Gook Pharmaceutical	5.3x	n/a	₩80.9b
A000227 Yuyu Pharma	42.7x	n/a	₩73.8b

Price-To-Earnings vs Peers: A000227 is expensive based on its Price-To-Earnings Ratio (42.7x) compared to the peer average (15.4x).

Price to Earnings Ratio vs Industry

How does A000227's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	37.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	37.4%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: A000227 is expensive based on its Price-To-Earnings Ratio (42.7x) compared to the KR Pharmaceuticals industry average (14.5x).

Price to Earnings Ratio vs Fair Ratio

What is A000227's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A000227 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	42.7x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A000227's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.